Literature DB >> 18327209

Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior.

Jason X Cheng1, Maria Tretiakova, Can Gong, Saptarshi Mandal, Thomas Krausz, Jerome B Taxy.   

Abstract

Renal medullary carcinoma is a rare, well-recognized highly aggressive tumor of varied histopathology, which occurs in young patients with sickle cell trait or disease. Rhabdoid elements, occasionally seen in high-grade renal tumors including renal medullary carcinoma, possibly represent a pathologic marker of aggressive behavior. INI1 (hSNF5/SMARCB1/BAF47) is a highly conserved factor in the ATP-dependent chromatin-modifying complex. Loss of this factor in mice results in aggressive rhabdoid tumors or lymphomas. In humans, the loss of INI1 expression has been reported in pediatric renal rhabdoid tumors, central nervous system atypical teratoid/rhabdoid tumors and epithelioid sarcomas, a possible primary soft tissue rhabdoid tumor. This study compares five renal medullary carcinomas with 10 high-grade renal cell carcinomas (five with rhabdoid features), two urothelial carcinomas and two pediatric renal rhabdoid tumors. All five renal medullary carcinomas, irrespective of histopathology, showed complete loss of INI1 expression similar to that seen in pediatric renal rhabdoid tumors. In contrast, all renal cell carcinomas or urothelial carcinomas, including those with histological rhabdoid features, expressed INI1. Clinically, all five of the patients with renal medullary carcinoma and the two patients with rhabdoid tumors presented with extra-renal metastases at the time of diagnosis. This study demonstrates that renal medullary carcinoma and renal rhabdoid tumor share a common molecular/genetic alteration, which is closely linked to their aggressive biological behavior. However, the absence of INI1 expression is not necessarily predictive of rhabdoid histopathology but remains associated with aggressive behavior in renal medullary carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327209     DOI: 10.1038/modpathol.2008.44

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  61 in total

1.  Pediatric Renal Cell Carcinoma.

Authors:  Elizabeth J Perlman
Journal:  Surg Pathol Clin       Date:  2010-09-01

Review 2.  Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer.

Authors:  Bernard Weissman; Karen E Knudsen
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 3.  Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.

Authors:  Simon Chowdhury; Marc R Matrana; Christopher Tsang; Bradley Atkinson; Toni K Choueiri; Nizar M Tannir
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

4.  Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors.

Authors:  Lisa M Sullivan; Theresa Yankovich; Paul Le; Daniel Martinez; Mariarita Santi; Jaclyn A Biegel; Bruce R Pawel; Alexander R Judkins
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

5.  SMARCB1/INI1 alterations and hepatoblastoma: another extrarenal rhabdoid tumor revealed?

Authors:  Pierre Russo; Jaclyn A Biegel
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

6.  Coexistent loss of INI1 and BRG1 expression in a rhabdoid renal cell carcinoma (RCC): implications for a possible role of SWI/SNF complex in the pathogenesis of RCC.

Authors:  Qiu Rao; Qiu-Yuan Xia; Qin Shen; Shan-Shan Shi; Pin Tu; Qun-Li Shi; Xiao-Jun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

7.  Cutaneous syncytial myoepithelioma: clinicopathologic characterization in a series of 38 cases.

Authors:  Vickie Y Jo; Cristina R Antonescu; Lei Zhang; Paola Dal Cin; Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

8.  Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas.

Authors:  Portia A Kreiger; Alexander R Judkins; Pierre A Russo; Jaclyn A Biegel; Brian J Lestini; Chatchawin Assanasen; Bruce R Pawel
Journal:  Mod Pathol       Date:  2008-11-07       Impact factor: 7.842

9.  Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.

Authors:  Pavlos Msaouel; Andrew L Hong; Elizabeth A Mullen; Michael B Atkins; Cheryl Lyn Walker; Chung-Han Lee; Marcus A Carden; Giannicola Genovese; W Marston Linehan; Priya Rao; Maria J Merino; Howard Grodman; Jeffrey S Dome; Conrad V Fernandez; James I Geller; Andrea B Apolo; Najat C Daw; H Courtney Hodges; Marva Moxey-Mims; Darmood Wei; Donald P Bottaro; Michael Staehler; Jose A Karam; W Kimryn Rathmell; Nizar M Tannir
Journal:  Clin Genitourin Cancer       Date:  2018-09-12       Impact factor: 2.872

10.  Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors.

Authors:  Eric M Jackson; Angela J Sievert; Xiaowu Gai; Hakon Hakonarson; Alexander R Judkins; Laura Tooke; Juan Carlos Perin; Hongbo Xie; Tamim H Shaikh; Jaclyn A Biegel
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.